2434-2435 / 2953
Adjuvant HT: 18 vs 36 months (PCS IV
trial)
•
Median follow-up 77
months
•
10 year overall survival
–
63.6% (18 months) vs 63.2%
(38 months), p=0.429
•
10 year disease-specific
High risk prostate cancer
(T3-4 or
PSA >20 ng/mL or Gleason score >7)
(n=630)
Pelvic RT
(whole pelvis 44 Gy/4½ weeks,
survival
–
87.2% (18 months) vs 87.2%
(36 months), p=0.838
•
No significant differences in
biochemical, regional or
distant failure between
arms
Nabid A, et al. ASCO GU 2013; Abstract 3
prostate 70 Gy/7 weeks)
GnRH agonist
for 18
months
(n=320)
GnRH agonist
for 36 months
(n=310)
Randomized
HT, hormone therapy; RT, radiotherapy